Rhaeos Inc. scooped up $10.5 million in a series A financing round led by Steele Foundation for Hope, with participation from Creative Ventures and Lateral Capital. The funds will be used to support the hospital launch of its Flowsense wearable hydrocephalus shunt monitor.
Transcend Therapeutics Inc. has closed on a series A funding of $40 million for its next-generation compound, methylone, an MDMA analogue, to be developed as a rapid-acting, disease-modifying, non-hallucinogenic treatment for neuropsychiatric conditions, including post-traumatic stress disorder.
The use of anti-CD20 therapies has revolutionized treatment options for multiple sclerosis (MS) patients, reducing relapses and halting disease progression. While CD20 is primarily expressed by B cells at different stages, a small T-cell subset also expresses CD20, and therefore anti-CD20 therapies also directly and indirectly affect T cells.
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described haloacethydrazide compounds acting as legumain (asparaginyl endopeptidase; LGMN; AEP) inhibitors reported to be useful for the treatment of subacute sclerosing panencephalitis, progressive supranuclear palsy, frontotemporal dementia and Alzheimer's disease, among others.
Louisiana State University has disclosed 5-HT2 receptor ligands reported to be useful for the treatment of anxiety, depression, asthma, chronic obstructive pulmonary disease (COPD), Alzheimer's disease, rheumatoid arthritis, chronic pain and post-stress traumatic disorder, among others.
Despite pleas from patient advocacy groups and bipartisan pressure from the U.S. Congress, the Centers for Medicare & Medicaid Services (CMS) isn’t budging on its national coverage determination for amyloid-targeting monoclonal antibodies approved to treat Alzheimer’s.
Microglial cells (MGs) are resident immune cells in the brain, which play a key role in the acute response and chronic recovery to stroke. Investigators at the University of Texas Health Science Center Houston aimed to evaluate MG transcriptomic response to stroke in mouse brain.
South Korean biotech peers Celltrion Healthcare Co. Ltd. and Liscure Biosciences Co. Ltd. signed a deal to co-develop microbiome-based oral live biotherapeutic products for Parkinson's disease. Under the agreement, Celltrion, of Incheon, South Korea, will provide Seoul-based Liscure with research funding as well as additional payments as the project progresses. Liscure will lead discovery of the novel candidates, and Celltrion will be responsible for further clinical and regulatory development.
PTC Therapeutics Inc. has synthesized heteroaryl compounds acting as huntingtin (HTT) (mutant) expression inhibitors reported to be useful for the treatment of Huntington's disease.
RSS
